Literature DB >> 20587789

Renal microvascular disease determines the responses to revascularization in experimental renovascular disease.

Alejandro R Chade1, Silvia Kelsen.   

Abstract

BACKGROUND: Percutaneous transluminal renal angioplasty (PTRA) is the most frequent therapeutic approach to resolving renal artery stenosis (RAS). However, renal function recovers in only 30% of the cases. The causes of these poor outcomes are still unknown. We hypothesized that preserving the renal microcirculation distal to RAS will improve the responses to PTRA. METHODS AND
RESULTS: RAS was induced in 28 pigs. In 14, vascular endothelial growth factor (VEGF)-165 0.05 microg/kg was infused intrarenally (RAS+VEGF). Single-kidney function was assessed in all pigs in vivo using ultrafast CT after 6 weeks. Observation of half of the RAS and RAS+VEGF pigs was completed. The other half underwent PTRA and repeated VEGF, and CT studies were repeated 4 weeks later. Pigs were then euthanized, the stenotic kidney removed, renal microvascular (MV) architecture reconstructed ex vivo using 3D micro-CT, and renal fibrosis quantified. The degree of RAS and hypertension were similar in RAS and RAS+VEGF. Renal function and MV density were decreased in RAS but improved in RAS+VEGF. PTRA largely resolved RAS, but the improvements of hypertension and renal function were greater in RAS+VEGF+PTRA than in RAS+PTRA, accompanied by a 34% increase in MV density and decreased fibrosis.
CONCLUSIONS: Preservation of the MV architecture and function in the stenotic kidney improved the responses to PTRA, indicating that renal MV integrity plays a role in determining the responses to PTRA. This study indicates that damage and early loss of renal MV is an important determinant of the progression of renal injury in RAS and instigates often irreversible damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587789      PMCID: PMC3032938          DOI: 10.1161/CIRCINTERVENTIONS.110.951277

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  32 in total

1.  Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect.

Authors:  R C Hendel; T D Henry; K Rocha-Singh; J M Isner; D J Kereiakes; F J Giordano; M Simons; R O Bonow
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

2.  Cell-based VEGF delivery prevents donor cell apoptosis after transplantation.

Authors:  Lei Ye; Husnain Kh Haider; Changfa Guo; Eugene K W Sim
Journal:  Ann Thorac Surg       Date:  2007-03       Impact factor: 4.330

3.  Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT.

Authors:  Elena Daghini; Andrew N Primak; Alejandro R Chade; James D Krier; Xiang-Yang Zhu; Erik L Ritman; Cynthia H McCollough; Lilach O Lerman
Journal:  Radiology       Date:  2007-05       Impact factor: 11.105

4.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

Authors:  T D Henry; K Rocha-Singh; J M Isner; D J Kereiakes; F J Giordano; M Simons; D W Losordo; R C Hendel; R O Bonow; S M Eppler; T F Zioncheck; E B Holmgren; E R McCluskey
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

Review 5.  Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension.

Authors:  Adeera Levin; Stuart Linas; Friedrich C Luft; Arlene B Chapman; Stephen Textor
Journal:  Am J Nephrol       Date:  2007-03-21       Impact factor: 3.754

6.  Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function.

Authors:  J D Krier; E L Ritman; Z Bajzer; J C Romero; A Lerman; L O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2001-10

7.  Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.

Authors:  D H Kang; S Anderson; Y G Kim; M Mazzalli; S Suga ; J A Jefferson; K L Gordon; T T Oyama; J Hughes; C Hugo; D Kerjaschki; G F Schreiner; R J Johnson
Journal:  Am J Kidney Dis       Date:  2001-03       Impact factor: 8.860

8.  Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.

Authors:  B Bussolati; C Dunk; M Grohman; C D Kontos; J Mason; A Ahmed
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

9.  Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function.

Authors:  Duk-Hee Kang; Jeremy Hughes; Marilda Mazzali; George F Schreiner; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

Review 10.  Renal artery stenosis: a common, treatable cause of renal failure?

Authors:  S C Textor; C S Wilcox
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

View more
  36 in total

Review 1.  Atherosclerotic renal artery stenosis: current status.

Authors:  Soon Hyo Kwon; Lilach O Lerman
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 2.  Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.

Authors:  Alejandro R Chade
Journal:  Hypertension       Date:  2017-02-13       Impact factor: 10.190

Review 3.  Chronic renal ischemia in humans: can cell therapy repair the kidney in occlusive renovascular disease?

Authors:  Ahmed Saad; Sandra M Herrmann; Stephen C Textor
Journal:  Physiology (Bethesda)       Date:  2015-05

4.  Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Zilun Li; Behzad Ebrahimi; Xin Zhang; Hui Tang; Michael J Korsmo; Alejandro R Chade; Joseph P Grande; Christopher J Ward; Robert D Simari; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-21       Impact factor: 8.311

Review 5.  Novel therapeutic strategies for renovascular disease.

Authors:  Alfonso Eirin; Stephen C Textor; Lilach O Lerman
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

6.  Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney.

Authors:  Silvia Kelsen; Xiaochen He; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

7.  Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Authors:  Erika Guise; Jason E Engel; Maxx L Williams; Fakhri Mahdi; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

8.  Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.

Authors:  Alejandro R Chade; Maxx L Williams; Erika Guise; Luke J Vincent; Taylor W Harvey; Marija Kuna; Fakhri Mahdi; Gene L Bidwell
Journal:  Kidney Int       Date:  2017-12-19       Impact factor: 10.612

Review 9.  Mitochondria: a pathogenic paradigm in hypertensive renal disease.

Authors:  Alfonso Eirin; Amir Lerman; Lilach O Lerman
Journal:  Hypertension       Date:  2014-11-17       Impact factor: 10.190

Review 10.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.